Moderna (MRNA) shares slipped sharply late on Thursday after the biotech firm’s cancer-vaccine trial results circulated ahead of their scheduled presentation. Oncology Central reportedly published the leaked data before removing its article, but screenshots had already spread across social media.
Despite the recent decline, Moderna stock has been a blockbuster investment in 2026, currently trading at roughly 6x its price at the start of this year.